Saxagliptin
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Saxagliptin |
| DrugBank ID | DB06335 |
| Brand Names (EU) | Onglyza |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.09% |
Approved Indication (EMA)
Add-on combination therapy Onglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control: as monotherapy: in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance; as dual oral therapy: in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control; in combination with a sulphonylurea, when t
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | opsismodysplasia | 98.09% | DL |
| 2 | classic stiff person syndrome | 97.66% | DL |
| 3 | focal stiff limb syndrome | 97.66% | DL |
| 4 | diabetes mellitus (disease) | 97.59% | DL |
| 5 | thiamine-responsive dysfunction syndrome | 97.50% | DL |
| 6 | drug-induced localized lipodystrophy | 96.35% | DL |
| 7 | pancreatic agenesis | 96.24% | DL |
| 8 | centrifugal lipodystrophy | 96.12% | DL |
| 9 | pressure-induced localized lipoatrophy | 96.02% | DL |
| 10 | idiopathic localized lipodystrophy | 95.75% | DL |
| 11 | autoimmune oophoritis | 85.22% | DL |
| 12 | type 1 diabetes mellitus | 82.18% | DL |
| 13 | cholangiocarcinoma, susceptibility to | 64.35% | DL |
| 14 | hemoglobin C-beta-thalassemia syndrome | 61.09% | DL |
| 15 | mitral valve prolapse, myxomatous | 58.43% | DL |
| 16 | obsolete breast fibroadenosis | 58.15% | DL |
| 17 | congenital temporomandibular joint ankylosis | 57.74% | DL |
| 18 | atrial flutter (disease) | 57.73% | DL |
| 19 | obsolete functional visual loss | 57.67% | DL |
| 20 | familial chronic myelocytic leukemia-like syndrome | 57.62% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.